Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2021

View Archived Issues

New clotting cofactor-binding anticoagulant RNA aptamers presented

Enanta Pharmaceuticals synthesizes new anti-HBV compounds

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent AKT1/AKT2/AKT3 inhibitors

New GABA(A) receptor agonists described by Sumitomo Dainippon Pharma

New antibacterials discovered at Merck & Co.

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical patent A2A/A2B receptor antagonists

New HIF-2alpha inhibitors discovered at Arcus Biosciences

DPX-SurMAGE dual T-cell therapy targeting MAGE-A9 and survivin shows promise in animal studies

Presepsin levels may be associated with COVID-19 mortality

Pharmacogenetic study identifies FKBP5 gene variants linked to treatment-resistant depression

SBIR grant supports POP Biotechnologies' development of theramostable vaccine for COVID-19

Mirati Therapeutics describes discovery and activity of GTPase KRAS inhibitor MRTX-1133

Recombinant AAVs for targeted gene delivery to muscle identified by a directed evolution approach

Filling the glass by emptying cancer cells' plates

Glycogen phosphorylase identified as a therapeutic target for anaplastic thyroid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...